Selected SummaryStep-Up and Top-Down Approaches to the Treatment of Crohn's Disease: Early May Already Be Too Late
Section snippets
Comment
This study is particularly relevant because it is the first study to investigate differences between treatment regimens for intervention in CD. However, several aspects of the trial should be taken into account. Even though the primary objective of the study was reached (remission without corticosteroids and without bowel resection at weeks 26 and 52), the study design is such that long-term, definitive conclusions cannot be drawn.
First, this was an unblinded randomized trial. Unblinding was
References (0)
Cited by (23)
Low-dose biologics to treat inflammatory bowel disease. Ready for prime time?
2019, Digestive and Liver DiseaseReply
2010, Clinical Gastroenterology and HepatologyLow-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease
2010, Clinical Gastroenterology and HepatologyCitation Excerpt :One could speculate that in the postsurgical setting Crohn's disease may be much more responsive to medical therapy because of the relatively short natural history and the absence of complications. In addition, early phases of disease may be driven by cytokines (eg, TNF-α) different from those of late phases (reviewed by Peyrin-Biroulet et al27). Our study does not clarify whether treatment with more than 3 infusions at the lower doses of infliximab (1 and 2 mg/kg bw) would have shown efficacy in restoring mucosal integrity.
Prognostic tools for identification of high risk in people with Crohn’s disease: Systematic review and cost-effectiveness study
2021, Health Technology AssessmentGenetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
2017, Journal of Translational Medicine